Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | KAT7 | O95251 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15919233 | 0.87 | MMP1 (0.46) | MMP1MMP3MMP7MMP9GPR119 | |
| SCHEMBL15919232 | 0.87 | MMP1 (0.46) | MMP1MMP3MMP7MMP9GPR119 | |
| SCHEMBL17800494 | 0.86 | MMP1 (0.53) | MMP1MMP3MMP7MMP9GPR119 | |
| SCHEMBL21360309 | 0.80 | SCN9A (0.46) | GPR119JAK2JAK1 | |
| SCHEMBL15915752 | 0.80 | ALOX5AP (0.69) | — | |
| SCHEMBL15915753 | 0.80 | ALOX5AP (0.69) | — | |
| SCHEMBL14490331 | 0.80 | MMP1 (0.57) | MMP1MMP3MMP7MMP9GPR119 | |
| SCHEMBL11946505 | 0.80 | STS (0.53) | MMP1MMP3MMP7MMP9GPR119 | |
| SCHEMBL21623350 | 0.79 | MAPT (0.49) | F13A1TGM2TGM1POLB | |
| SCHEMBL21624588 | 0.79 | MAPT (0.49) | F13A1TGM2TGM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318412-A1 | Tricyclic heterocyclic compound and use thereof | HTR2C, HTR2A, HTR5A | MMP1 3543/4885MMP3 2539/4885MMP7 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.